** Shares of Florida-based drug developer MIRA Pharmaceuticals MIRA.O fall 8.6% to $1.17 premarket
** Agrees to buy privately held Delaware-based SKNY Pharmaceuticals in a stock deal to add experimental weight-loss drug candidate - regulatory filing
** SKNY-1 is an experimental oral drug in preclinical development for weight-loss and smoking cessation
** Says SKNY will contribute $5 million in cash or assets at close
** MIRA marginally up in the past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.